The Significance of CK18 and Azonulin when Evaluating Nonalcoholic Fatty Liver Diseases in the Iraqi Community

Nawal Abdullah Murtadha

doi:10.51699/cajmns.v6i4.3002

Authors

Nawal Abdullah Murtadha College of Science, University Of Kirkuk, Iraq

DOI:

https://doi.org/10.51699/cajmns.v6i4.3002

Keywords:

Nonalcoholic fatty liver disease, cytokeratin 18, zonulin

Abstract

Nonalcoholic fatty liver disease (NAFLD), which impacts over twenty-five percent of the worldwide population, has emerged as an important issue for the public. This prevalent liver disease is characterized by excess fat buildup after hepatic steatosis, with or without hepatocyte loss, various types of inflammatory cells infiltration, nonalcoholic steatohepatitis, and, in rare instances, cirrhosis and cancer of the liver. Cytokeratin 18 (CK18), which is a marker of apoptosis and overall cell death, is an excellent biomarker for NAFLD. Liver fat accumulation in NAFLD triggers the activation of caspases, which increases the CK18 cleavage and its release into the blood. CK18 can help diagnose different stages of NAFLD, especially the nonalcoholic steatohepatitis (NASH) stage. CK18 is important for assessing the success of NAFLD treatment and forecasting the risk of NAFLD-related illnesses. The zonulin test can detect intestinal permeability among individuals with nonalcoholic fatty liver disease (NAFLD), which is typically elevated.

References

M. L. Sanyal, J. Van Natta, J. Clark, et al. , "Prospective study of outcomes in adults with non-alcoholic fatty liver disease," N Engl J Med, vol. 385, no. 17, pp. 1559-1569, 2021.

H. Chen, "Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease," Liver Research, vol. 4, no. 1, pp. 15-22, 2020.

A. M. Wasme, M. S. Sailh, Y. H. Tahseen, and A. K. Abdulla, "Association of some Biochemical Markers, Hepatitis B, and C Viruses with Type 2 Diabetes Mellitus in Kirkuk City/Iraq," Central Asian Journal of Medical and Natural Science, vol. 6, no. 2, pp. 578-585, 2025

W. Li and W. Alazawi, "Non-alcoholic fatty liver disease," Clin. Med. (London, England), vol. 20, no. 5, pp. 509-512, 2020.

S. Rana and N. Prabhakar, "Iron disorders and hepcidin," Clinica Chimica Acta, vol. 523, pp. 454-468, 2021.

V. Ajmera, E. R. Perito, N. M. Bass, N. A. Terrault, K. P. Yates, R. Gill, et al. , "Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease," J. Hepatol. , vol. 65, no. 1, pp. 65–77, 2017.

I. G. Zainal, S. A. Al, and W. K. Obead, "Comparison of glycoproteins levels with some biochemical parameters in Iraqi patients with chronic liver diseases," Innovative Journal of Medical and Health Science, vol. 5, no. 2, pp. 89-93, 2012.

I. Mikolasevic, L. Orlic, L. Zaputovic, S. Racki, Z. Cubranic, K. Anic, et al. , "The usefulness of liver test and controlled attenuation parameter in the detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease," Wien Klin Wochenschr. , vol. 127, no. 11-12, pp. 451-458, 2015.

C. E. Ruhl and J. E. Everhart, "Elevated Serum Alanine Aminotransferase and γ-Glutamyltransferase and Mortality in the United States Population," J. Gastroenterol. , vol. 136, no. 2, pp. 477-485. e11, 2009.

H. H. Bragulla and D. G. Homberger, "Structure and functions of keratin proteins in simple, stratified, keratinized, and cornified epithelia," J Anat. , vol. 214, no. 4, pp. 516-559, 2009.

A. Wieckowska, N. N. Zein, L. M. Yerian, A. R. Lopez, A. J. McCullough, and A. E. Feldstein, "In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease," J. Hepatol. , vol. 44, no. 1, pp. 27-33, 2006.

A. M. ElGhandour, et al. , "Value of zonulin as a diagnostic and prognostic marker in different degrees of nonalcoholic fatty liver disease," Egyptian Liver Journal, vol. 14, no. 1, pp. 43, 2024.

A. Y. Aida, H. Abe, Y. Tomita, T. Nagano, N. Seki, T. Sugita, et al. , "Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease," Int J Clin Exp Med. , vol. 7, no. 11, pp. 4191–8, 2014.

R. Kathak, R. Raihanu, et al. , "The association between elevated lipid profile and liver enzymes: a study on Bangladeshi adults," Scientific Reports, vol. 12, no. 1, pp. 1711, 2022.

Q. Li, et al. , "Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio has a non-linear association with non-alcoholic fatty liver disease: A secondary prospective cohort study in non-obese Chinese adults," Front. Med. , vol. 9, pp. 995749, 2022.

L. W. Chen, et al. , "Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study," Kaohsiung J. Med. Sci. , vol. 37, no. 9, pp. 819-827, 2021.

A. Hadinia, et al. , "Circulating levels of pro-inflammatory cytokines in patients with nonalcoholic fatty liver disease and non-alcoholic steatohepatitis," Iranian J. Immunol. , vol. 16, no. 4, pp. 327-333, 2019.

A. Ali, et al. , "Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among Type-2 diabetics," Pakistan J. Med. Sci. , vol. 38, no. 1, pp. 28, 2022.

X. Ma, et al. , "Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis," BMC Gastroenterol. , vol. 20, pp. 1-8, 2020.

T. Wong, R. J. Wong, and R. G. Gish, "Diagnostic and treatment implications of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis," Gastroenterology & Hepatology, vol. 15, no. 2, pp. 83, 2019.

Y. B. Won, et al. , "Non-alcoholic fatty liver disease in polycystic ovary syndrome women," Sci. Rep. , vol. 11, no. 1, pp. 7085, 2021.

H. Ou, et al. , "Association between smoking and liver fibrosis among patients with nonalcoholic fatty liver disease," Can. J. Gastroenterol. Hepatol. , 2019.

G. Ndrepepa, et al. , "Aspartate aminotransferase and mortality in patients with ischemic heart disease," Nutr. Metab. Cardiovasc. Dis. , vol. 30, no. 12, pp. 2335-2342, 2020.

J. M. Han, et al. , "Differing associations between fatty liver and dyslipidemia according to the degree of hepatic steatosis in Korea," J. Lipid Atheroscler. , vol. 8, no. 2, pp. 258-266, 2019.

R. Mansour-Ghanaei, et al. , "Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran," J. Fam. Med. Prim. Care. , vol. 8, no. 3, pp. 923-928, 2019.

R. S. Khan, et al. , "Modulation of insulin resistance in nonalcoholic fatty liver disease," Hepatology, vol. 70, no. 2, pp. 711-724, 2019.

N. N. Noori and N. A. Murtadha, "Uncontrolled type 2 diabetes mellitus modulated plasma levels of lipid catabolic proteins," Georgian Med. News, no. 7-8, pp. 352-353, 2024.

S. Q. Lai, et al. , "Sensitivity to thyroid hormone indices are closely associated with NAFLD," Front. Endocrinol. , vol. 12, pp. 766419, 2021.

S. A. Qassam, Z. K. Ahmed, and S. Z. Nada, "The role of biochemical markers in the assessment of non-alcoholic fatty liver disease in young Iraqi people," Iraq Med. J. , vol. 3, no. 2, pp. 2019.

M. M. Maher, W. A. Ibrahim, S. A. Saleh, L. Shash, H. Abou Gabal, M. Tarif, and M. Gamal, "Cytokeratin 18 as a non-invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients," Egypt J. Med. Hum. Genet. , vol. 16, no. 1, pp. 41–46, 2015.

A. E. Feldstein, N. Alkhouri, R. De Vito, A. Alisi, R. Lopez, and V. Nobili, "Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children," Am J Gastroenterol, vol. 108, no. 9, pp. 1526–1531, 2013.

J. Liang, F. Liu, F. Wang, T. Han, L. Jing, Z. Ma, and Y. Gao, "A noninvasive score model for prediction of NASH in patients with chronic hepatitis B and nonalcoholic fatty liver disease," BioMed Res. Int. , 2017, pp. 2017.

L. Pacifco, E. Bonci, L. Marandola, S. Romaggioli, B. S. Bascetta, and C. Chiesa, "Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease," World J. Gastroenterol. , vol. 20, no. 45, pp. 17107, 2014.

L. Zhu, S. S. Baker, and C. Gill, "Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH," Hepatology, vol. 57, no. 2, pp. 601–609, 2013.

A. Zak-Gołąb, P. Kocełak, M. Aptekorz, M. Zientara, L. Juszczyk, G. Martirosian, et al. , "Gut microbiota, microinfammation, metabolic profile, and zonulin concentration in obese and normal weight subjects," Int. J. Endocrinol. , vol. 2013, article 674106, 2013.